PDF Archive

Easily share your PDF documents with your contacts, on the Web and Social Networks.

Send a file File manager PDF Toolbox Search Help Contact



Osteosarcoma Clinical Trials.pdf


Preview of PDF document osteosarcoma-clinical-trials.pdf

Page 1 2 3 4 5

Text preview


Eleison is currently developing ILC, a breakthrough
therapeutic for the treatment of patients with a
rare form of bone cancer known as osteosarcoma .
INHALED LIPID-COMPLEXED CISPLATIN - “ILC”
● Engineered specifically for nebulized lung delivery.
● Patented lipid formulation of cisplatin in ~0.4 μm particles deliver sustained
drug release in the lung.
● Concentrations in lung at least 10x higher and systemic toxicities much lower
than intravenous dosing of cisplatin.
● Safety data showed no hematologic toxicity, nephrotoxicity, ototoxicity, or
neurotoxicity.